Daily therapy with VALTREX reduces recurrences of genital herpes.1,2
- VALTREX offers simple once-daily dosing because it has 3 to 5 times greater bioavailability than acyclovir3,4
- 1 g QD - recommended dosage of VALTREX for patients with recurrent genital herpes
- 500 mg QD - alternative dosage of VALTREX in patients with <9 recurrences/year
- Favorable safety profile with daily therapy* - safety and tolerability information on suppression with VALTREX
Patients on VALTREX 1 g QD suppression can be outbreak-free for almost a year*1,2
- At 1 year, 34% of patients taking VALTREX 1 g once daily stayed outbreak-free vs 4% of patients taking placebo1,2
- At 1 year, 31% of patients taking VALTREX 500 mg† once daily stayed outbreak-free vs 3% of patients taking placebo1,2
Results from a 52-week randomized, prospective, multicenter, double-blind trial of 1479 immunocompetent patients with genital herpes who received daily VALTREX, acyclovir, or placebo. All patients enrolled had a history of 6 or more recurrences/year.
No data are available on the efficacy of treatment of more than 1 year's duration for suppression.
*In immunocompetent adults.
†Recommended dosage for suppression is 1 g QD. In patients with ≤9 recurrences/year, an alternative dosage is 500 mg QD.
‡ 500-mg data are from a post-hoc subset analysis focused on patients with a history of 6 to 9 recurrences per year.
†Recommended dosage for suppression is 1 g QD. In patients with ≤9 recurrences/year, an alternative dosage is 500 mg QD.
‡ 500-mg data are from a post-hoc subset analysis focused on patients with a history of 6 to 9 recurrences per year.
